Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
XYF-13 by Xi'An Yufan Biotechnology for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
XYF-13 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...